Cangene Reports Third Quarter 2012 Results

Readers are referred to the cautionary notes regarding Forward-looking Information and non-IFRS Financial Measures at the end of this release. Unless noted otherwise, all dollar amounts are in U.S. dollars.

TSX: CNJ

WINNIPEG, June 12, 2012 /CNW/ - Cangene Corporation today reports financial results for the third quarter of 2012, ended on April 30, 2012.

Revenues for the quarter were $27.5 million, compared with $34.2 million in the same quarter last year. The decrease in revenue is largely attributable to lower bulk sales of non-specialty plasma in the biopharmaceutical-operations segment. The Company also recognized lower product-services revenue on its anthrax immune globulin ("AIG") contract, compared with the same quarter last year, which included a delivery of AIG product. Deliveries on the AIG contract were completed in 2011. These decreases in revenue were partially offset by activity in the contract-services segment in the current-year quarter, which included plasma deliveries on the botulism antitoxin ("BAT") contract and higher contract-manufacturing revenue at Cangene's Baltimore-based subsidiary, Cangene bioPharma, Inc., compared with the same quarter last year.

Net loss for the current quarter of $4.6 million, compares with a net loss of $1.4 million in the same quarter last year. The greater net loss in the current quarter results largely from lower revenues and gross margins on biopharmaceutical product sales and a smaller tax benefit, but was partially offset by a reduction in selling, general and administrative expenses and a smaller foreign-exchange loss. A loss per share for the current quarter of $0.07 compares with a loss per share of $0.02 in the same quarter last year.

"The 2012 fiscal year has been one of great transition for Cangene, and we have made many positive changes in the organization," says John Sedor, President and CEO of Cangene. "As we work towards redefining our corporate priorities, we believe that we will be well positioned to generate added value for our stakeholders," adds Mr. Sedor.

As at April 30, 2012, Cangene had a cash balance of $43.4 million and no debt. Cash used in operations, excluding changes in working capital, was $3.0 million for the current quarter, compared with cash flow of $0.1 million in the same quarter last year. The net change in non-cash working capital for the quarter was a decrease of $12.7 million, primarily due to lower accounts receivable and taxes recoverable, with the result that cash provided by operations in the quarter was $9.7 million.

Certain comparative figures in the following financial statements have been reclassified to conform to the current year's presentation.

Incorporated under the laws of Ontario
Cangene Corporation

CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS (unaudited)

in thousands of U.S. dollars At April 30, 2012 At July 31, 2011
         
ASSETS        
Current        
Cash $ 43,436   $ 45,176
Accounts receivable   18,995     20,083
Inventories and contracts in progress   64,861     67,177
Taxes recoverable   5,520     12,220
Prepaid expenses and deposits   1,744     2,334
Total current assets   134,556     146,990
Property, plant and equipment, net   68,951     74,175
Taxes recoverable   16,589     16,288
Deferred tax   17,048     16,338
Intangible assets, net   9,986     12,305
  $ 247,130   $ 266,096
         
LIABILITIES AND EQUITY        
Current        
Accounts payable and accrued liabilities $ 15,894   $ 18,219
Derivative financial instruments   1,022     1,775
Provision for chargebacks   3,473     3,664
Incentive plan liability   1,113    
Taxes payable   30     92
Current portion of deferred income   3,732     3,207
Total current liabilities   25,264     26,957
Deferred income   5,713     6,716
Royalty provision   2,277     3,316
Incentive plan liability   1,283     2,844
Deferred share unit liability   473     222
Deferred tax   1,456     2,841
Total liabilities   36,466     42,896
         
Equity        
Share capital   50,860     50,860
Contributed surplus   353    
Retained earnings   159,451     172,340
Total equity   210,664     223,200
  $ 247,130   $ 266,096

Cangene Corporation
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF LOSS AND COMPREHENSIVE LOSS (unaudited)

in thousands of U.S. dollars except share-related data Three months
ended
April 30,2012
Three months
    ended
April 30, 2011
Nine months
  ended
April 30, 2012
Nine months
  ended
  April 30, 2011
                 
Revenues                
Product sales $ 10,473   $ 17,019   $ 35,100   $ 39,366
Product services   12,386     11,594     34,144     42,991
R&D services   4,665     4,775     13,333     12,642
Royalties       847         2,478
    27,524     34,235     82,577     97,477
                 
Cost of sales                
Product sales   9,406     13,620     27,346     26,831
Product services   8,609     6,817     22,968     30,008
R&D services   3,415     3,321     9,716     9,335
    21,430     23,758     60,030     66,174
                 
Gross profit   6,094     10,477     22,547     31,303
                 
Expenses                
Independent R&D   4,454     4,579     18,085     10,086
Selling, general and administrative   6,455     7,570     21,272     22,855
Impairment of property, plant and equipment           5    
Impairment of intangible assets           636    
Loss (gain) on sale of assets   36     (125)     127     (87)
    10,945     12,024     40,125     32,854
Operating loss   (4,851)     (1,547)     (17,578)     (1,551)
Short-term interest income   25     17     39     43
Foreign-exchange gain (loss)   (842)     (3,633)     2,877     (5,592)
                 
Loss before taxes   (5,668)     (5,163)     (14,662)     (7,100)
                 
Tax expense (benefit)                
  Current   457     (2,034)     322     (3,603)
  Deferred   (1,542)     (1,737)     (2,095)     (543)
    (1,085)     (3,771)     (1,773)     (4,146)
Net loss and comprehensive loss for the period $ (4,583)   $ (1,392)   $ (12,889)   $ (2,954)
                 
Loss per share                
  Basic and diluted $ (0.07)   $ (0.02)   $ (0.19)   $ (0.04)

Cangene Corporation
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY (unaudited)

in thousands of U.S. dollars Stated share
  capital
Retained
earnings
Contributed
surplus
Total
Balance at July 31, 2010 $ 51,696   $ 173,295   $   $ 224,991  
Net income for the year ended July 31, 2011       1,509         1,509  
Common shares purchased and cancelled under NCIB   (836 )   (2,464 )       (3,300 )
Balance at July 31, 2011   50,860     172,340         223,200  
                 
Net loss for the nine-month period ended April 30, 2012       (12,889 )       (12,889 )
Stock option expense           353     353  
Balance at April 30, 2012 $ 50,860   $ 159,451   $ 353   $ 210,664  
                 
Balance at July 31, 2010 $ 51,696   $ 173,295   $   $ 224,991  
Net loss for the nine-month period ended April 30, 2011       (2,954 )       (2,954 )
Common shares purchased and cancelled under NCIB   (766 )   (2,325 )       (3,091 )
Balance at April 30, 2011 $ 50,930   $ 168,016   $   $ 218,946  

Cangene Corporation
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (unaudited)

in thousands of U.S. dollars Three months
  ended
  April 30, 2012
Three months
  ended
  April 30, 2011
Nine months
  ended
  April 30, 2012
Nine months
  ended
  April 30, 2011
                 
OPERATING ACTIVITIES                
Net loss for the period $ (4,583 ) $ (1,392 ) $ (12,889 ) $ (2,954 )
Add (deduct) items not involving cash:                
  Depreciation of property, plant and equipment   2,145     2,478     6,459     7,599  
  Amortization of intangible assets   631     681     1,957     2,047  
  Deferred income   (961 )   (911 )   (478 )   (1,886 )
  Incentive plan liability   7     (217 )   (448 )   299  
  Deferred share unit liability   92     35     251     110  
  Amortization of royalty provision   (193 )   (228 )   (642 )   (848 )
  Revaluation of royalty provision   558     (156 )   (397 )   (1,736 )
  Deferred tax benefit   (1,542 )   (1,737 )   (2,095 )   (543 )
  Change in value of derivative financial instruments   704     1,686     (753 )   2,649  
  Loss (gain) on disposal of assets   36     (125 )   127     (87 )
  Impairment of intangible assets           636      
  Impairment of property, plant and equipment           5      
  Stock option expense   89         353      
Net change in non-cash working capital balances related to operations   12,744     10,544     7,815     (4,229 )
Cash provided by (used in) operating activities   9,727     10,658     (99 )   421  
                 
INVESTING ACTIVITIES                
Purchase of property, plant and equipment, net   (263 )   (1,235 )   (1,401 )   (6,857 )
Acquisition of intangible assets   (49 )   (106 )   (240 )   (219 )
Proceeds on disposal of assets       140         140  
Cash used in investing activities   (312 )   (1,201 )   (1,641 )   (6,936 )
                 
FINANCING ACTIVITIES                
Shares repurchased for cancellation       (550 )       (3,091 )
Cash used in financing activities       (550 )       (3,091 )
Net increase (decrease) in cash during the period   9,415     8,907     (1,740 )   (9,606 )
Cash, beginning of period   34,021     21,853     45,176     40,366  
Cash, end of period $ 43,436   $ 30,760   $ 43,436   $ 30,760  
                 
Interest paid1 $ 9   $ 6   $ 15   $ 13  
Taxes paid2 $ (10,411 ) $ (3,373 ) $ (10,352 ) $ (3,347 )
  1. Amounts paid and received for interest were reflected as operating cash flows in the consolidated statements of cash flows.
  2. Amounts paid and received for income taxes were reflected as either operating or investing cash flows in the consolidated statements
    of cash flows, depending upon the nature of the underlying transaction.

About Cangene Corporation
Cangene Corporation (TSX: CNJ), headquartered in Winnipeg, Canada, is one of the nation's oldest and largest biopharmaceutical companies and it is focused on the development and commercialization of hospital-based therapeutics. Cangene's products are sold worldwide and include products that have been accepted into the U.S. Strategic National Stockpile. Cangene has approximately 580 employees in six locations across North America. It operates manufacturing facilities in Winnipeg, Manitoba, and Baltimore, Maryland (through its wholly-owned subsidiary Cangene bioPharma, Inc.), where it produces its own products and undertakes contract manufacturing for a number of customers. Cangene operates three U.S. and one Canadian plasma-collection facilities operating under the name Cangene Plasma Resources. For more information about Cangene, go to the Company's website at: www.cangene.com.

Cautionary note regarding Forward-looking Information
This document contains forward-looking statements about the Corporation, including its business operations, strategy, and expected financial performance and condition. Forward-looking statements include statements that are predictive in nature, depend upon or refer to future events or conditions, or include words such as "expects", "anticipates", "intends", "plans", "will", "believes", "estimates", or negative versions thereof, and similar expressions. In addition, any statement that may be made concerning future financial performance (including revenues, earnings or growth rates); ongoing business strategies or prospects; future use, safety and efficacy of unapproved products or unapproved uses of products; and possible future action by the Corporation are also forward-looking statements. Forward-looking statements are based on current expectations and projections about future events and are inherently subject to, among other things, risks, uncertainties and assumptions about the Corporation, economic factors and the biopharmaceutical industry generally. They are not guarantees of future performance. Actual events and results could differ materially from those expressed or implied by forward-looking statements made by the Corporation due to, but not limited to, important factors such as sales levels; fluctuations in operating results; the Corporation's reliance on a small number of customers including government organizations; the demand for new products and the impact of competitive products, service and pricing; the availability and cost of raw materials, and in particular, the cost, availability and antibody concentration in plasma; progress and cost of clinical trials; costs and possible development delays resulting from use of legal, regulatory or legislative strategies by the Corporation's competitors; uncertainty related to intellectual property protection and potential costs associated with its defence as well as general economic, political and market factors in North America and internationally; interest and foreign-exchange rates; business competition; technological change; changes in government action, policies or regulations; changes in accounting policies and the effect of applying future accounting policy changes required under IFRS; unexpected judicial or regulatory proceedings; catastrophic events; the Corporation's ability to complete strategic transactions; and other factors beyond the control of management.

The reader is cautioned that the foregoing list of important factors is not exhaustive and there may be other factors listed in other filings with securities regulators, including factors set out under "Risk and Uncertainties" in the Corporation's Management Discussion and Analysis, which, along with other filings, is available for review at www.sedar.com. The reader is also cautioned to consider these and other factors carefully and not to place undue reliance on forward-looking statements. Other than as specifically required by applicable law, the Corporation has no intention to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Cautionary Note Regarding Non-IFRS Financial Measures
This news release may contain non-IFRS financial measures. Terms by which non-IFRS financial measures are identified include but are not limited to "net cash", "total assets", "sales" and other similar expressions. Non-IFRS financial measures are used to provide management and investors with additional measures of performance. However, non-IFRS financial measures do not have standard meanings prescribed by IFRS and are not directly comparable to similar measures used by other companies. Please refer to the appropriate reconciliations of these non-IFRS financial measures to measures prescribed by IFRS.

 

SOURCE Cangene Corporation

For further information:

Contact Information
John A. Sedor
President and Chief Executive Officer
Ph:  (204) 275-4201
Email: jsedor@cangene.com

Profil de l'entreprise

Cangene Corporation

Renseignements sur cet organisme


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.